welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Tucson drug startup launches gastric-cancer trial
Tucson-based drug startup Cancer Prevention Pharmaceuticals Inc. has announced the launch of a Phase 2 clinical trial at Vanderbilt University Medical Center to test the company’s flagship drug candidate for preventing gastric cancer.
The drug, CPP-1X, will be studied in patients with precancerous gastric lesions who are at high risk for gastric cancer, the company said Monday.
The trial is funded by the National Cancer Institute and run in collaboration with gastroenterologists Dr. Keith T. Wilson and Dr. Douglas R. Morgan of the Vanderbilt University School of Medicine and the Vanderbilt-Ingram Cancer Center.
expertly curated content related to this topic
- Molecular Fluorescence Endoscopy in Patients With Familial Adenomatous Polyposis, Using Bevacizumab-IRDye800CWThere is a need for better visualization...
- Laparoscopic Colectomy and Restorative Proctocolectomy for Familial Adenomatous PolyposisBACKGROUND : Familial adenomatous polypo...
- Familial Investigations of Childhood Cancer PredispositionWhile it is well recognized that heredit...
- Celecoxib, DFMO combination improved adenoma burden in patients with familial adenomatous polyposisIn a randomized clinical chemoprevention...
- Small Bowel Endoscopic Evaluation in Familial Adenomatous Polyposis (FAP)Background and study aim The relative ri...
- Impact of a Hospital-based Register on the Management of Familial Adenomatous PolyposisColorectal cancer in familial adenomatou...
- Coping and relaxation techniques with medical procedureshttps://www.youtube.com/watch?v=_tUhIYzA...
English
Portuguese